BVS

Bioventus

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/05/26

Business Summary

Bioventus operates in the medical device space, generating revenue by developing and commercializing clinically oriented products that address musculoskeletal and related therapeutic areas. Cash flow is driven by product sales into healthcare providers, where recurring procedural usage and physician adoption create repeat demand. Its moat is built on regulatory approvals, clinical validation, and entrenched relationships with distributors and providers rather than on pure patent lock-in. Scale in commercialization and established reimbursement pathways create switching friction, allowing the company to defend margins while extracting steady revenue from procedural healthcare demand.

VALUATION

P/E

27.5

Market Cap ($M USD)

$610

Forward P/E

10.4

PEG

-

PRICE TO SALES

1.1

PRICE TO BOOK

3.3

EV / EBITDA

8.6

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$0.34

Next Year EPS Growth Estimate

$0.88

Next Year Revenue Growth Estimate

6.90%

Return on Equity (ROE)

12.40%

Operating Margin

9.90%

Debt-to-Equity

1.6

Piotroski F-Score

8

Altman Z-Score

1.4

Return on Invested Capital (ROIC)

9.10%%

Current Ratio

1.7

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At $610M market cap, BVS screens like a dislocated small-cap with conflicting signals. A 27.5 P/E paired with a sharply lower 10.4 Forward P/E implies a dramatic earnings inflection, yet the Altman Z-Score of 1.4 places the company in financial distress territory, meaning the equity carries real balance sheet risk. The market is clearly discounting something structural, but with a Piotroski F-Score of 8 and ROIC of 9.10%, operations are not collapsing. This is not a clean growth story—it is a leveraged turnaround trading at a compressed forward multiple where survival risk and earnings recovery are battling for dominance.

AI Exposure / Tech Reliance

As a Medical Devices company within Healthcare, BVS operates in a segment where AI integration is more incremental than disruptive. Device optimization, data-driven treatment pathways, and digital integration can enhance product value, but this is not a pure software scalability story. Its resilience depends more on clinical adoption and reimbursement stability than on technological reinvention.

The Bull Case

A GARP or deep value investor would focus on the operational quality embedded in the numbers. A Piotroski F-Score of 8 signals strong internal financial momentum, while a 12.40% operating margin in medical devices suggests pricing power and cost discipline. ROIC at 9.10% exceeding many capital costs in small-cap healthcare implies value creation, not destruction. The Forward P/E of 10.4 against a current P/E of 27.5 suggests earnings normalization or acceleration, and with a Price/Sales of 1.1 and Price/Book of 3.3, the stock is not priced like a high-flying med-tech growth name. Add a 1.6 TTM yield and 1.7 current ratio, and you have a company that appears operationally stable but sentiment-depressed—exactly the kind of asymmetry value funds hunt.

The Bear Case

The balance sheet is the obvious pressure point. A Debt/Equity ratio of 9.90% combined with an Altman Z-Score of 1.4 signals financial fragility, and in small-cap healthcare that can quickly spiral if reimbursement or demand softens. The absence of a PEG Forward ratio removes visibility into whether growth justifies valuation, while several missing sentiment indicators like Short % of Float limit transparency into market skepticism. EPS of 8.6 versus EPS Next Year estimate of $0.34 introduces severe earnings volatility, and inconsistency like that is precisely what destroys investor confidence. This is not a steady compounder—it is a company walking a narrow path between recovery and capital stress.

Market Sentiment & Smart Money

Short Interest %

5.40%

Analyst Consensus

1.33

Average Analyst Price Target

$14.80

Institutional Ownership %

77.90%

1-Year Beta

1.09

Insider Buying % (6 Mo)

11.80%%

Distance to 52-Week High

95.10%%

Distance to 52-Week Low

155.90%%